258 results
Page 10 of 13
8-K
7brtbc2vw871 m8te
26 May 20
Regulation FD Disclosure
8:30am
8-K
EX-99.1
u4gvom
7 May 20
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
8:30am
8-K
EX-1.1
puby7f qi
28 Apr 20
Entry into a Material Definitive Agreement
4:28pm
424B5
3su dunmh3ftkkz2c
28 Apr 20
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
iodgvz4dsjq9u woruz
27 Apr 20
Regulation FD Disclosure
4:18pm
424B5
bukdzp4o1u2wj98qzn
27 Apr 20
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
wjhumj2yys3
16 Apr 20
Entry into a Material Definitive Agreement
8:49am
424B5
uo8fk76a9afzh
16 Apr 20
Prospectus supplement for primary offering
8:44am
8-K
ym2in uiu
8 Apr 20
Other Events
7:30am
8-K
EX-99.1
99wz pqhwp8430a1f7
24 Feb 20
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
7:30am
8-K/A
jrlr mecc
13 Jan 20
Regulation FD Disclosure
5:20pm
8-K
EX-99.2
fdlskxnia79mprr0
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
qutw9gclkgtr8pawj
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
EX-99.1
ki2ehfk
3 Dec 19
Regulation FD Disclosure
8:00am